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After a nihilistic period lasting for decades, major progress in nonsmall cell lung cancer (NSCLC) therapy
were linked to the introduction of platinum-based regimens, third generation chemotherapeutic drugs and,
more recently, with the discovery of oncogenic driver mutations and the development of very effective
targeted therapies [1]. However, for a long time, despite known significant immune dysregulations in the
lung cancer environment, clinical trials with immune therapy failed to be superior to standard therapy.
Adjuvant vaccination was one of the most recent prominent failures [2]. Fundamental research led to a
better knowledge of immune cell cycle control and the recognition of the role of immune checkpoints,
e.g. cytotoxic T-lymphocyte associated 4 (CTLA4) and programmed death-1 (PD1) and programmed
death-ligand 1 (PDL1) complexes [3, 4]. This rapidly resulted in clinical application with different
immune checkpoint inhibitors (ICI, monoclonal antibodies). In a 3-year period, the European Medicines
Agency and the US Food and Drug Administration approved four distinct ICI for treatment of NSCLC,
either in the metastatic setting or adjuvant in stage III NSCLC.
A part of the European Respiratory Society’s thoracic oncology assembly research seminar entitled “New
biomarkers, molecules and therapeutic sequences for NSCLC in the era of precision medicine”, held in
May 2019 in Paris, was dedicated to the achievements and future developments in ICI. This seminar
joined international experts in the field as well as clinicians, researchers and basic scientists. We herein
summarise the main points on ICI results, implementation and perspectives in NSCLC.
Several pharmaceutical companies, starting with phase I and continuing up to phase III trials, developed
complex research processes with anti-PD1 and anti-PDL1. Rapidly, signals of activity associated with a
good toxicity profile came from the anti-PD1 nivolumab and pembrolizumab in heavily pre-treated stage
IV NSCLC [5]. Importantly, updated data showed long-term disease control, with around 10% 5-year
survival without recurrent disease [6]: impressive data never reported previously in this population. After
the first promising results, phase II/III trials were conducted in second line for relapsed metastatic NSCLC
(table 1). Five randomised phase II–III trials testing three ICI (nivolumab, pembrolizumab and
Received: 26 Sept 2019 | Accepted after revision: 22 Nov 2019
Copyright ©ERS 2020
https://doi.org/10.1183/13993003.01907-2019 Eur Respir J 2020; 55: 1901907
| EDITORIALLUNG CANCER
atezolizumab), all showed a clinically and statistically significant advantage over the same standard
comparator docetaxel [7–9, 11, 18]. Long-term data were presented and confirmed a long-lasting effect of
ICI on overall survival.
Next, those ICI were tested as first line treatment in stage IV NSCLC but showed some conflicting results
(table 1). Monotherapy with pembrolizumab demonstrated significant survival superiority over
platinum-based doublets only in a selected group of patients (tumour PDL1 ⩾50%) [11, 12], while this
was not achieved with nivolumab [13]. Conversely, combination of pembrolizumab with chemotherapy
had better activity than chemotherapy alone, without excessive supplemental toxicity [14, 15] regardless of
the histological subtype or the PDL1 value. Furthermore, atezolizumab showed interesting activity in
non-squamous NSCLC, provided bevacizumab was added to the chemotherapy combination [16], but the
activity of this drug remains questionable in squamous histology.
Based on these impressive results, ICI were tested in locoregional NSCLC. The only published phase III trial
demonstrated that adjuvant durvalumab in stage III NSCLC non-progressing after concomitant
chemo-radiotherapy improved not only progression-free but also overall survival [17]. Also, an early clinical
study showed that neo-adjuvant nivolumab before surgical resection led to 40% major pathological
response [19]. In this evolving landscape, unpublished phase II and III trials showed promising results [20]
with lower major pathological response rates in immunotherapy alone regimens (22% for atezolizumab in
LCM3, and 31% for nivolumab with/without ipilimumab in NEOSTAR) than for chemo-immunotherapy
regimens (77% for chemotherapy plus nivolumab in NADIM, and 64% for chemotherapy plus
atezolizumab). Currently, three large phase III trials are conducted in completely resected stage IB–IIIA
NSCLC testing pembrolizumab, nivolumab or durvalumab in an adjuvant strategy. The best sequence for
adding immunotherapy to surgery, before or after resection, as well as the integration with chemotherapy
needs to be clarified.
As thoracic oncologists did for targeted therapies, clinicians have to learn managing specific toxicities
related to the mechanism of action of anti-PD1/PDL1 ICI. Despite some preferential sites being
documented, immune-related adverse events may reach any organ at any time, which is different from
chemotherapy and targeted therapies. In most of the randomised trials [7–18], ICI monotherapy is well
tolerated (few grade 3–5 adverse events) and discontinuation of treatment for immune-related adverse
events is around 5%, while combinations of anti-PD1/PDL1 and anti-CTL4, such as nivolumab–
ipilimumab, are associated with up to 10% grade 3–5 toxicity. Immune-related adverse events such as
hypo/hyperthyroidism are observed in up to 10–15% of the patients and might occur as late toxicity;
otherwise, the most frequent immune-related adverse events are those affecting the lung, colon, skin and
liver, that in some instances could be life-threatening, as well as those considered to be more unusual, such
as myocarditis or hypopituitarism. Furthermore, renal failure and interstitial nephritis are potentially
problematic in patients receiving ICI–chemotherapy combinations (platinum–pemetrexed). This implies
TABLE 1 Selected results of practice-changing immunotherapy randomised phase III trials
References Treatment Median survival times p-value
Second-line
BRAHMER et al. [7] Nivolumab versus docetaxel 9.2 months versus 6 months <0.001
BORGHAEI et al. [8] Nivolumab versus docetaxel 12.2 months versus 9.4 months 0.002
HERBST et al. [9] Pembrolizumab versus docetaxel 10.4/12.7 months versus 8.5 months <0.001
RITTMEYER et al. [10] Atezolizumab versus docetaxel 13.8 months versus 9.6 months 0.0003
First-line: immunotherapy
versus chemotherapy
RECK et al. [11] Pembrolizumab versus platinum doublet HR 0.60 (95% CI 0.41–0.89)# 0.005
MOK et al. [12] Pembrolizumab versus platinum doublet 16.7 months versus 12.1 months 0.0018
CARBONE et al. [13] Nivolumab versus platinum doublet 14.4 months versus 13.2 months NS
First-line: chemo-immunotherapy
versus chemotherapy
PAZ-ARES et al. [14] CBDCA-(nab)PTX±pembrolizumab 15.9 months versus 11.3 months <0.001
GANDHI et al. [15] CDDP/CBDCA-PEM±pembrolizumab NR versus 11.3 months <0.001
SOCINSKI et al. [16] CBDCA-PTX-beva±atezolizumab 19.2 months versus 14.7 months 0.02
Adjuvant in stage III
ANTONIA et al. [17] Durvalumab versus placebo NR versus 28.7 months 0.0025
HR: hazard ratio; NS: not significant; NR: not reached; CBDCA: carboplatin; PTX: paclitaxel; CDDP: cisplatin; PEM: pemetrexed; beva:
bevacizumab. #: no median survival available in the manuscript.
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active detection and management by the thoracic oncologist in conjunction with organ specialists, as well
as the conduct of dedicated clinical trials.
These major achievements led to substantial modifications in the therapeutic algorithm for stage III–IV
NSCLC and currently, most of those patients are receiving anti-PD1/PDL1 ICI in first or eventually
second line and adjuvant after concomitant chemoradiotherapy, as currently reported in the 2019 ESMO
guidelines [21].
However, numerous questions remain, and were approached in the seminar during fruitful discussions
(table 2). Faced with expensive drugs, it is important to define the patients who will most benefit, knowing
that up to 30% may present with early progression and/or hyperprogression. Only one validated predictive
biomarker is standardised and routinely available, but the accuracy of PDL1 is not sufficient for an
individual prediction test in most instances. Other biomarkers, including tumour mutational burden,
specific molecular alterations (SKT11, KEAP1) or some immune signatures, are undergoing testing with
interesting preliminary results that should be confirmed in prospective studies [29, 30]. A second
important question is regarding the management of brain metastases (BM). In almost all randomised
trials, patients were only eligible if BM were previously treated and stable. Very limited data [31] suggested
that ICI are active on BM, needing further confirmation. Lastly, the best therapeutic algorithm remains to
be defined: is an ICI–chemotherapy regimen more active than ICI in the PDL1 ⩾50% subgroup? Is
maintenance chemotherapy necessary in those treated with ICI–chemotherapy, or is maintenance ICI
sufficient? Which is the role of anti-CTLA4 antibodies? Is combination of ICI (anti-PD1/PDL1 plus
anti-CTLA4) an interesting option, may other antigen-delivering agents (vaccination, radiotherapy,
targeted drugs, etc.) improve ICI effectiveness? Can ICI be delivered to initially contra-indicated (HIV,
TABLE 2 Summary of some important questions in nonsmall cell lung cancer (NSCLC) immunotherapy
Population Incidence in
NSCLC patients
Summary of available data Conclusion
ECOG PS ⩾2 [22] Up to 25% • Limited data, often retrospective
• Limited benefit of monotherapy ICI
• ORR around 11–12%
• Median overall survival around 3.6–5.4 months,
in PDL1 TPS ⩾50% 16.6 months
• Less response and reduced survival duration
• ICI cannot be endorsed in this population
without caution
Baseline PDN
use of
⩾10 mg·day−1 [23]
11–20% • Only retrospective data
• Lower ORR and overall survival compared to
PDN <10 mg·day−1 (p<0.001)
• Suggestion that PDN only deleterious when
given for cancer related cause
• Possibly populations with distinct intrinsic
prognosis instead of a direct effect from
steroids
• Caution to use baseline steroids
Elderly [24] Trials <10%
Daily
practice 27%
• Also ICI benefit for overall survival in elderly
patients but increased risk for
immune-related adverse events
• ICI can be given to older patients
Auto-immune
disorders [25]
14–25% • Mainly retrospective data
• Higher rate of immune-related adverse events
in those with auto-immune disorder compared
to those without
• Time to immune-related adverse events shorter
in those with auto-immune disorder
• Survival not different
• ICI can be given to patients with
auto-immune disorders, especially those
without immunosuppressive medication
but at increased risk of immune-related
adverse events
Brain metastases [26] Trials 9–17.5%
Daily
practice 25%
• Trials: conflicting data
• Real world: conflicting data. If corrected for ECOG PS
and baseline steroids no deleterious effect of brain
metastases
• ICI can be given to patients with asymptomatic
brain metastases in non-eloquent areas
with close imaging follow-up
Driver mutations [25] Up to 20–25% • Trials: no benefit for EGFR/ALK+ patients when
treated with monotherapy ICI, suggestions benefit
for carboplatin/paclitaxel/beva/atezolizumab
• Retrospective data: in drivers associated
with non-smoking, no benefit monotherapy ICI
• ICI are only option in driver-mutated patients
when other treatment lines are exhausted
HIV [27, 28] Not specified • Review and phase I data: ICI seem safe in HIV,
and also beneficial
• No pejorative effect on viral load and CD4 cell count
• ICI may be an option in HIV patients
ECOG: Eastern Cooperative Oncology Group; PS: performance status; PDN: prednisolone; ICI: immune checkpoint inhibitor; ORR: objective
response rate; PDL1: programmed death ligand 1; TPS: tumour proportion score; EGFR: epidermal growth factor receptor: ALK: anaplastic
lymphoma kinase; beva: bevacizumab.
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chronic viral infection, auto-immune disease, renal insufficiency) and other specific populations (poor
performance status, elderly, etc.)? What is the optimal duration of immunotherapy and how do we select
patients in whom ICI can be stopped without resulting in disease progression? What is the role of
rechallenge ICI? How can hyperprogressive patients be identified, and does hyperprogression exist in
chemotherapy-ICI treated patients? What are, besides PDL1, biomarkers that can select patients for ICI
treatment (or that can identify patients that should not receive ICI at all)? Can patients be re-treated at
disease progression when ICI was previously stopped and patients benefited? Is the occurrence of
immune-related adverse events a possible prognostic and/or predictive marker of ICI efficacy?
Despite reproducible positive results, only a minority (<20%) of the patients derived a very long-term
benefit from ICI immunotherapy and most will progress at any time during treatment. Different strategies
are under development and tested in clinical trials, such as new targets, bispecific antibodies, add-in of
antigen-delivering drug/technique, combinations with radiotherapy, etc. [32].
In conclusion, immunotherapy with anti-PD1/PDL1 antibodies profoundly modified our vision in treating
locally advanced and metastatic NSCLC and it will probably modify the treatment of earlier disease
NSCLC. Currently, immunotherapy alone (pembrolizumab) or in combination with chemotherapy
(pembrolizumab or atezolizumab) is standard of care for first-line therapy in stage IV NSCLC, while new
immunotherapy combinations such as nivolumab–ipilimumab may be another option in a near future.
Durvalumab is now the first immunotherapy validated for adjuvant treatment in stage III NSCLC
non-progressing after concomitant radiochemotherapy. Many questions remain unresolved and should be
clarified in the near future. Those are of importance when considering the financial impact of these drugs
if we aim for sustainable, viable health systems.
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